Annual EBIT
-$47.67 M
+$3.05 M+6.02%
December 31, 2023
Summary
- As of February 7, 2025, GRTX annual earnings before interest & taxes is -$47.67 million, with the most recent change of +$3.05 million (+6.02%) on December 31, 2023.
- During the last 3 years, GRTX annual EBIT has risen by +$21.69 million (+31.27%).
- GRTX annual EBIT is now -101.31% below its all-time high of -$23.68 million, reached on December 31, 2018.
Performance
GRTX EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBIT
-$5.78 M
-$1.72 M-42.32%
September 1, 2024
Summary
- As of February 7, 2025, GRTX quarterly earnings before interest & taxes is -$5.78 million, with the most recent change of -$1.72 million (-42.32%) on September 1, 2024.
- Over the past year, GRTX quarterly EBIT has dropped by -$902.00 thousand (-18.48%).
- GRTX quarterly EBIT is now -42.32% below its all-time high of -$4.06 million, reached on June 30, 2024.
Performance
GRTX Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBIT
-$19.11 M
+$7.20 M+27.37%
September 1, 2024
Summary
- As of February 7, 2025, GRTX TTM earnings before interest & taxes is -$19.11 million, with the most recent change of +$7.20 million (+27.37%) on September 1, 2024.
- Over the past year, GRTX TTM EBIT has increased by +$28.56 million (+59.91%).
- GRTX TTM EBIT is now -260.52% below its all-time high of -$5.30 million, reached on September 30, 2018.
Performance
GRTX TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBIT Formula
EBIT = Revenue − COGS − Operating Expenses
GRTX EBIT Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +6.0% | -18.5% | +59.9% |
| 3 y3 years | +31.3% | -18.5% | +59.9% |
| 5 y5 years | -101.3% | -18.5% | +59.9% |
GRTX EBIT Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +35.0% | -42.3% | +64.5% | at high | +73.9% |
| 5 y | 5-year | at high | +35.0% | -42.3% | +72.6% | at high | +75.4% |
| alltime | all time | -101.3% | +35.0% | -42.3% | +72.6% | -260.5% | +75.4% |
Galera Therapeutics EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$5.78 M(+42.3%) | -$19.11 M(-27.4%) |
| Jun 2024 | - | -$4.06 M(-7.2%) | -$26.31 M(-31.8%) |
| Mar 2024 | - | -$4.38 M(-10.3%) | -$38.56 M(-19.1%) |
| Dec 2023 | -$47.67 M(-6.0%) | -$4.88 M(-62.4%) | -$47.67 M(-14.5%) |
| Sep 2023 | - | -$12.99 M(-20.4%) | -$55.72 M(+0.4%) |
| Jun 2023 | - | -$16.31 M(+21.0%) | -$55.52 M(+8.7%) |
| Mar 2023 | - | -$13.49 M(+4.3%) | -$51.07 M(+0.7%) |
| Dec 2022 | -$50.72 M(-30.8%) | -$12.93 M(+1.1%) | -$50.72 M(-3.0%) |
| Sep 2022 | - | -$12.79 M(+7.8%) | -$52.28 M(-12.6%) |
| Jun 2022 | - | -$11.86 M(-9.7%) | -$59.79 M(-13.4%) |
| Mar 2022 | - | -$13.14 M(-9.3%) | -$69.02 M(-5.9%) |
| Dec 2021 | -$73.34 M | -$14.49 M(-28.6%) | -$73.34 M(-5.6%) |
| Sep 2021 | - | -$20.30 M(-3.7%) | -$77.67 M(+6.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2021 | - | -$21.08 M(+20.7%) | -$73.22 M(+5.4%) |
| Mar 2021 | - | -$17.46 M(-7.3%) | -$69.49 M(+0.2%) |
| Dec 2020 | -$69.35 M(+41.8%) | -$18.83 M(+18.8%) | -$69.35 M(+4.7%) |
| Sep 2020 | - | -$15.84 M(-8.7%) | -$66.27 M(+5.4%) |
| Jun 2020 | - | -$17.36 M(+0.2%) | -$62.86 M(+11.6%) |
| Mar 2020 | - | -$17.32 M(+10.0%) | -$56.32 M(+15.2%) |
| Dec 2019 | -$48.91 M(+106.5%) | -$15.74 M(+26.6%) | -$48.91 M(+17.6%) |
| Sep 2019 | - | -$12.43 M(+14.9%) | -$41.59 M(+20.7%) |
| Jun 2019 | - | -$10.82 M(+9.2%) | -$34.46 M(+45.8%) |
| Mar 2019 | - | -$9.91 M(+17.6%) | -$23.64 M(+72.2%) |
| Dec 2018 | -$23.68 M(-0.9%) | -$8.43 M(+58.9%) | -$13.73 M(+158.9%) |
| Sep 2018 | - | -$5.30 M | -$5.30 M |
| Dec 2017 | -$23.91 M | - | - |
FAQ
- What is Galera Therapeutics annual earnings before interest & taxes?
- What is the all time high annual EBIT for Galera Therapeutics?
- What is Galera Therapeutics annual EBIT year-on-year change?
- What is Galera Therapeutics quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for Galera Therapeutics?
- What is Galera Therapeutics quarterly EBIT year-on-year change?
- What is Galera Therapeutics TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for Galera Therapeutics?
- What is Galera Therapeutics TTM EBIT year-on-year change?
What is Galera Therapeutics annual earnings before interest & taxes?
The current annual EBIT of GRTX is -$47.67 M
What is the all time high annual EBIT for Galera Therapeutics?
Galera Therapeutics all-time high annual earnings before interest & taxes is -$23.68 M
What is Galera Therapeutics annual EBIT year-on-year change?
Over the past year, GRTX annual earnings before interest & taxes has changed by +$3.05 M (+6.02%)
What is Galera Therapeutics quarterly earnings before interest & taxes?
The current quarterly EBIT of GRTX is -$5.78 M
What is the all time high quarterly EBIT for Galera Therapeutics?
Galera Therapeutics all-time high quarterly earnings before interest & taxes is -$4.06 M
What is Galera Therapeutics quarterly EBIT year-on-year change?
Over the past year, GRTX quarterly earnings before interest & taxes has changed by -$902.00 K (-18.48%)
What is Galera Therapeutics TTM earnings before interest & taxes?
The current TTM EBIT of GRTX is -$19.11 M
What is the all time high TTM EBIT for Galera Therapeutics?
Galera Therapeutics all-time high TTM earnings before interest & taxes is -$5.30 M
What is Galera Therapeutics TTM EBIT year-on-year change?
Over the past year, GRTX TTM earnings before interest & taxes has changed by +$28.56 M (+59.91%)